This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Blood sugar tracking is officially general-wellness territory. Abbott announced Thursday that its prescription-free continuous glucose monitor, Lingo, is now available for sale in the US.

Given its better prospects, we believe Abbott stock (NYSE: ABT) is a better pick than its peer Medtronic stock (NYSE: MDT). ABT stock trades at 4.9x trailing revenues, versus 3.6x for MDT.

This was the stock's third consecutive day of losses.

Abbott (ABT) closed the most recent trading day at $113.70, moving -0.39% from the previous trading session. Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price target of $133.00. The company’s shares ...

Summary. In 2008 Abbott introduced a revolutionary new device, FreeStyle Navigator, designed to improve the lives of the world’s more than 500 million diabetes patients by offering continuous ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...

Abbott Elementary: L-R: William Stanford Davis, Lisa Ann Walter, Tyler James Williams, Sheryl Lee Ralph, Chris Perfetti, Janelle James, Quinta Brunson (front/center) ABC EXCLUSIVE: ABC’s Abbott ...

ABBOTT PARK, Ill., Sept. 4, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep ...